ArticleJournal of the American Society of Nephrology : JASN2015
Cause-Specific Deaths in Non-Dialysis-Dependent CKD.
Article in Journal of the American Society of Nephrology : JASN, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03832166 (A Prospective, Randomized Two Group Study to Evaluate the Feasibility and Initial Efficacy of a Community-engaged Screening, Identification, and F&V Intervention to Improve F&V Intake and CKD Outcomes in 140 AA Adults), which is not on this map. Cited by 76 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective, Randomized Two Group Study to Evaluate the Feasibility and Initial Efficacy of a Community-engaged Screening, Identification, and F&V Intervention to Improve F&V Intake and CKD Outcomes in 140 AA Adults
Who cites it
76 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).The Cochrane database of systematic reviews · 2025Pooled it
- Chronic kidney disease and risk of kidney or urothelial malignancy: systematic review and meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024Pooled it
- A systematic review and meta-analysis of the clinical impact of stopping renin-angiotensin system inhibitor in patients with chronic kidney disease.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Pooled it
- A randomized trial of serological and cellular responses to hepatitis B vaccination in chronic kidney disease.PloS one · 2018Trial
- Kidney-Vascular Metabolic Crosstalk: Altered Lipoproteins in CKD.Circulation research · 2026Review
- Adverse Muscle Composition Is Associated with All-Cause Mortality in CKD: A UK Biobank Imaging Study.Clinical journal of the American Society of Nephrology : CJASN · 2026Article
- Gaining Community Trust Enables Research Designed to Reduce the National Burden of Chronic Kidney Disease.Journal of immigrant and minority health · 2026Review
- New hypothesis: a gut-lipid-kidney axis in constipated CKD patients-insights from multi-omics triangulation.mSphere · 2026Article
- The role of sarcopenia in all-cause mortality prediction among community-dwelling adults with eGFR 15-89 mL/min/1.73 mOpen medicine (Warsaw, Poland) · 2026Article
- Nephrology Provider Perceptions about Recommending Influenza and COVID-19 Vaccines: A Nationwide Survey.American journal of nephrology · 2026Article
- Genome-wide polygenic risk score for estimated glomerular filtration slope predicts chronic kidney disease in a Taiwanese population.Journal of nephrology · 2025Article
- Lower absolute numbers of CD4Renal failure · 2025Article
- Physical activity and cardiorenal health-from associations to interventional studies.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Review
- Galectin-3 Is Associated With Risk of Cardiovascular and Kidney Outcomes in Ambulatory Veterans.Kidney medicine · 2025Article
- Patient Activation Impacts Exercise in Older Adults With Kidney Disease.Kidney international reports · 2025Article
- SerumLife (Basel, Switzerland) · 2025Article
- Metabolic, renal, and inflammatory crosstalk in atherosclerotic cardiovascular disease: Evolving landscape and future directions.Atherosclerosis · 2025Review
- The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025Article
- Quality of life in older immigrant adults on hemodialysis.PloS one · 2025Article
- Cardiovascular and Kidney Outcomes of Non-Diabetic CKD by Albuminuria Severity: Findings From the CRIC Study.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2024Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
5 authors.
Funding
Abstract
CKD is associated with higher risk of death, but details regarding differences in cause-specific death in CKD are unclear. We examined the leading causes of death among a non-dialysis-dependent CKD population using an electronic medical record-based CKD registry in a large healthcare system and the Ohio Department of Health mortality files. We included 33,478 white and 5042 black patients with CKD who resided in Ohio between January 2005 and September 2009 and had two measurements of eGFR<60 ml/min per 1.73 m(2) obtained 90 days apart. Causes of death (before ESRD) were classified into cardiovascular, malignancy, and non-cardiovascular/non-malignancy diseases and non-disease-related causes. During a median follow-up of 2.3 years, 6661 of 38,520 patients (17%) with CKD died. Cardiovascular diseases (34.7%) and malignant neoplasms (31.8%) were the leading causes of death, with malignancy-related deaths more common among those with earlier stages of kidney disease. After adjusting for covariates, each 5 ml/min per 1.73 m(2) decline in eGFR was associated with higher risk of death due to cardiovascular disease (hazard ratio [HR], 1.10; 95% confidence interval [95% CI], 1.08 to 1.12) and non-cardiovascular/non-malignancy diseases (HR, 1.12; 95% CI, 1.09 to 1.14) but not to malignancy. In the adjusted models, blacks had overall-mortality hazard ratios similar to those of whites but higher hazard ratios for cardiovascular deaths. Further studies to confirm these findings and explain the mechanisms for differences are warranted. In addition to lowering cardiovascular burden in CKD, efforts to target known risk factors for cancer at the population level are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.